Oral oncology最新文献

英文中文

Letter to the editor “Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice” 致编辑的信 "新辅助化疗对边缘可切除口腔癌的长期疗效：3266名患者的真实数据及对临床实践的启示"。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-10 DOI: 10.1016/j.oraloncology.2024.106943

Silambarasan Tamil Selvan

引用次数: 0

Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer 医科学生对人类乳头瘤病毒和疫苗在头颈癌中的作用的认识和态度。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-10 DOI: 10.1016/j.oraloncology.2024.106939

Ali Ghalib Mutar Mahdi

Background

Papilloma DNA virus which is most common sexually transmitted disease to both sexes. The infection either benign or malignant affecting head and neck region.

Aim of the study

Assess the level of knowledge, and attitude, of medical students about Human Papilloma virus, vaccine, and its role in head and neck cancer development.

Materials and methods

A descriptive cross-sectional survey was conducted on 357 undergraduate medical students. Data were collected by online Google form researcher made questionnaires which was analyzed using SPSS 25.

Results

There are 357 medical undergraduate students from different educational stages participated in this study. This study was shown 176 (49.3 %) of medical students agreed that smoking Tobacco are the most common causes for development oral cancer followed by viruses 98 (27.5 %), that 57.4 % of medical students reported that HPV was the main viral cause. As for the questions concerning HPV mode of transmission, almost (85.7 %) stated sexual transmission, (79.8 %) skin to skin direct contact. Most of the participants (92.2 %) agreed that primary prevention can decrease the risk of infection with HPV, and 43.4 % strongly agreed that vaccination plays an important role in HPV prevention.

Conclusions

There is a requirement within the existing curriculum and syllabus to include more education, seminars, and training courses on HPV, role in HNC, prevention, and vaccination, and mainly for students in the preclinical academic years. Application of a virtual classroom viral module or communicating workshop would likely improve knowledge and attitudes of the students for their future medical tasks.

背景介绍乳头状瘤DNA病毒是两性最常见的性传播疾病。这种感染可能是良性的，也可能是恶性的，会影响头颈部：研究目的：评估医科学生对人类乳头瘤病毒、疫苗及其在头颈部癌症发展中的作用的了解程度和态度：对 357 名本科医学生进行了描述性横断面调查。数据通过研究人员制作的在线谷歌问卷收集，并使用 SPSS 25 进行分析：共有 357 名来自不同教育阶段的医学本科生参与了本研究。研究结果显示，176 名（49.3%）医学生认为吸烟是导致口腔癌的最常见原因，其次是病毒，98 名（27.5%）医学生认为人乳头瘤病毒是主要的病毒原因，57.4%的医学生认为人乳头瘤病毒是主要的病毒原因。关于人乳头瘤病毒传播方式的问题，几乎（85.7%）的人表示是性传播，（79.8%）表示是皮肤直接接触传播。大多数参与者（92.2%）同意初级预防可以降低感染人乳头瘤病毒的风险，43.4%的人非常同意疫苗接种在人乳头瘤病毒预防中发挥着重要作用：结论：在现有课程和教学大纲中，需要纳入更多有关 HPV、在 HNC 中的作用、预防和疫苗接种的教育、研讨会和培训课程，主要针对临床前学年的学生。应用虚拟教室病毒模块或交流研讨会可能会提高学生对未来医疗任务的认识和态度。

{"title":"Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer","authors":"Ali Ghalib Mutar Mahdi","doi":"10.1016/j.oraloncology.2024.106939","DOIUrl":"10.1016/j.oraloncology.2024.106939","url":null,"abstract":"<div><h3>Background</h3><p>Papilloma DNA virus which is most common sexually transmitted disease to both sexes. The infection either benign or malignant affecting head and neck region.</p></div><div><h3>Aim of the study</h3><p>Assess the level of knowledge, and attitude, of medical students about Human Papilloma virus, vaccine, and its role in head and neck cancer development.</p></div><div><h3>Materials and methods</h3><p>A descriptive cross-sectional survey was conducted on 357 undergraduate medical students. Data were collected by online Google form researcher made questionnaires which was analyzed using SPSS 25.</p></div><div><h3>Results</h3><p>There are 357 medical undergraduate students from different educational stages participated in this study. This study was shown 176 (49.3 %) of medical students agreed that smoking Tobacco are the most common causes for development oral cancer followed by viruses 98 (27.5 %), that 57.4 % of medical students reported that HPV was the main viral cause. As for the questions concerning HPV mode of transmission, almost (85.7 %) stated sexual transmission, (79.8 %) skin to skin direct contact. Most of the participants (92.2 %) agreed that primary prevention can decrease the risk of infection with HPV, and 43.4 % strongly agreed that vaccination plays an important role in HPV prevention.</p></div><div><h3>Conclusions</h3><p>There is a requirement within the existing curriculum and syllabus to include more education, seminars, and training courses on HPV, role in HNC, prevention, and vaccination, and mainly for students in the preclinical academic years. Application of a virtual classroom viral module or communicating workshop would likely improve knowledge and attitudes of the students for their future medical tasks.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads 辅助化疗对不同放疗中期Epstein-Barr病毒DNA血浆载量患者的疗效

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-05 DOI: 10.1016/j.oraloncology.2024.106938

Jie Chen , Hui Cheng , Yujing Liang , Jieyi Lin , Guodong Jia , Tianyi Wang , Yifu Li , Yu Chen , Pan Wang , Bowen Shen , Sailan Liu , Shanshan Guo , Qiuyan Chen , Linquan Tang , Haiqiang Mai , Liting Liu

Objectives

This study aimed to evaluate the efficacy of adjuvant chemotherapy (AC) in patients with different midpoint-radiotherapy (mid-RT) Epstein-Barr virus (EBV) DNA plasma loads for locoregionally advanced nasopharyngeal carcinoma (NPC), and to provide decision-making regarding the use of AC.

Materials and methods

A total of 675 consecutive patients diagnosed with stage III–IVa NPC were enrolled in this study. All patients underwent concurrent chemoradiotherapy (CCRT), either with or without induction chemotherapy or AC, or a combination of both. The primary endpoint of this study was progression-free survival (PFS).

Results

Among the 675 enrolled patients, 248 (36.7 %) received AC and 427 (63.3 %) were only observed after CCRT. In total, 149 (22.1 %) patients had detectable mid-RT EBV DNA levels, whereas 526 (77.9 %) had undetectable mid-RT EBV DNA levels. Patients with detectable mid-RT EBV DNA had worse 5-year PFS than those with undetectable mid-RT EBV DNA (74.8 % vs. 81.9 %, P = 0.045). AC group showed significantly better 5-year PFS than observation in patients with detectable mid-RT EBV DNA (82.8 % vs. 66.8 %; HR, 0.480; 95 % CI 0.250–0.919, P = 0.027). Multivariate analyses demonstrated that the treatment methods (AC vs. observation) were independent prognostic factors for PFS (HR, 0.37; 95 % CI 0.19–0.74, P = 0.005). However, in patients with undetectable mid-RT EBV DNA (5-year PFS: HR 0.873, 95 % CI 0.565–1.349, P = 0.52), AC group showed no survival benefit for observation.

Conclusion

AC could reduce the risk of disease progression compared to observation in patients with detectable mid-RT EBV DNA. Our findings suggest that AC is effective in patients at a high risk of treatment failure.

目的本研究旨在评估辅助化疗（AC）对局部晚期鼻咽癌（NPC）不同中期放疗（mid-RT）EB病毒（EBV）DNA血浆载量患者的疗效，并为AC的使用提供决策依据。材料和方法本研究共纳入了675例连续确诊的III-IVa期鼻咽癌患者。所有患者均接受了同期化放疗（CCRT），包括诱导化疗或 AC，或两者结合。研究的主要终点是无进展生存期（PFS）。结果675名入组患者中，248人（36.7%）接受了AC治疗，427人（63.3%）仅在CCRT后接受了观察。共有 149 例（22.1%）患者可检测到中段 RT EBV DNA 水平，而 526 例（77.9%）患者检测不到中段 RT EBV DNA 水平。与检测不到中段EBV DNA的患者相比，检测到中段EBV DNA的患者的5年PFS较差（74.8% vs. 81.9%，P = 0.045）。在检测到中段EBV DNA的患者中，AC组的5年生存期明显优于观察组（82.8% vs. 66.8%；HR，0.480；95% CI 0.250-0.919，P = 0.027）。多变量分析表明，治疗方法（AC 与观察）是 PFS 的独立预后因素（HR，0.37；95 % CI 0.19-0.74，P = 0.005）。然而，对于检测不到中段EBV DNA的患者（5年PFS：HR 0.873，95 % CI 0.565-1.349，P = 0.52），AC组与观察组相比没有生存获益。我们的研究结果表明，AC 对治疗失败风险较高的患者有效。

{"title":"The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads","authors":"Jie Chen , Hui Cheng , Yujing Liang , Jieyi Lin , Guodong Jia , Tianyi Wang , Yifu Li , Yu Chen , Pan Wang , Bowen Shen , Sailan Liu , Shanshan Guo , Qiuyan Chen , Linquan Tang , Haiqiang Mai , Liting Liu","doi":"10.1016/j.oraloncology.2024.106938","DOIUrl":"https://doi.org/10.1016/j.oraloncology.2024.106938","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to evaluate the efficacy of adjuvant chemotherapy (AC) in patients with different midpoint-radiotherapy (mid-RT) Epstein-Barr virus (EBV) DNA plasma loads for locoregionally advanced nasopharyngeal carcinoma (NPC), and to provide decision-making regarding the use of AC.</p></div><div><h3>Materials and methods</h3><p>A total of 675 consecutive patients diagnosed with stage III–IVa NPC were enrolled in this study. All patients underwent concurrent chemoradiotherapy (CCRT), either with or without induction chemotherapy or AC, or a combination of both. The primary endpoint of this study was progression-free survival (PFS).</p></div><div><h3>Results</h3><p>Among the 675 enrolled patients, 248 (36.7 %) received AC and 427 (63.3 %) were only observed after CCRT. In total, 149 (22.1 %) patients had detectable mid-RT EBV DNA levels, whereas 526 (77.9 %) had undetectable mid-RT EBV DNA levels. Patients with detectable mid-RT EBV DNA had worse 5-year PFS than those with undetectable mid-RT EBV DNA (74.8 % vs. 81.9 %, P = 0.045). AC group showed significantly better 5-year PFS than observation in patients with detectable mid-RT EBV DNA (82.8 % vs. 66.8 %; HR, 0.480; 95 % CI 0.250–0.919, P = 0.027). Multivariate analyses demonstrated that the treatment methods (AC vs. observation) were independent prognostic factors for PFS (HR, 0.37; 95 % CI 0.19–0.74, P = 0.005). However, in patients with undetectable mid-RT EBV DNA (5-year PFS: HR 0.873, 95 % CI 0.565–1.349, P = 0.52), AC group showed no survival benefit for observation.</p></div><div><h3>Conclusion</h3><p>AC could reduce the risk of disease progression compared to observation in patients with detectable mid-RT EBV DNA. Our findings suggest that AC is effective in patients at a high risk of treatment failure.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141542506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on ‘Mutation detection in saliva from oral cancer patients’ 关于 "口腔癌患者唾液中的突变检测 "的评论。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106937

Sreehari Suresh

引用次数: 0

Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence? 评论：人类乳头瘤病毒疫苗与头颈癌的预防，目前的证据是什么？

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106936

Raja Kannan

引用次数: 0

The prognostic value of pretreatment 18F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma 新发转移性鼻咽癌患者治疗前 18F-FDG PET-CT 参数与外周血标志物的预后价值。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106928

Li-wen Gu , Xu Zhang , Jing Zhang , Bei-bei Xiao , Li-ping Wu , Lin-quan Tang , Ling Guo , Li-ting Liu

Background and purpose

To develop and validate a prognostic nomogram based on pretreatment ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT)radiomics parameters and peripheral blood markers for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC).

Materials and Methods

A total of 558 patients with dmNPC were retrospectively enrolled between 2011 and 2019. Eligible patients were randomly divided into training and validation cohorts (7:3 ratio). A Cox regression model was used to identify prognostic factors for overall survival (OS). The predictive accuracy and discriminative ability of the prognostic nomogram were determined using the concordance index (C-index) and calibration curve.

Results

Independent factors derived from multivariable analysis of the training cohort to predict death were lactate dehydrogenase levels, pretreatment Epstein–Barr virus DNA, total lesion glycolysis of locoregional lesions, number of metastatic lesions, and age, all of which were assembled into a nomogram with (nomogram B) or without PET-CT parameters (nomogram A). The C-index of nomogram B for predicting death was 0.70, which was significantly higher than the C-index values for nomogram A. Patients were then stratified into low- and high-risk groups based on the scores calculated using nomogram B for OS. The median OS was significantly higher in the low-risk group than in the high-risk group (69.60 months [95 % CI: 58.50–108.66] vs. 21.40 months [95 % CI: 19.20–23.90]; p＜0.01). All the results were confirmed in the validation cohort.

Conclusion

The proposed nomogram including PET-CT parameters yielded accurate prognostic predictions for patients with dmNPC, enabling effective risk stratification for these patients.

背景和目的：根据治疗前18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（PET-CT）放射组学参数和外周血标志物，开发并验证用于对新发转移性鼻咽癌（dmNPC）患者进行风险分层的预后提名图：2011年至2019年期间，共回顾性纳入558例dmNPC患者。符合条件的患者被随机分为训练组和验证组（比例为7:3）。采用Cox回归模型确定总生存期（OS）的预后因素。使用一致性指数（C-index）和校准曲线确定预后提名图的预测准确性和判别能力：结果：通过对训练队列进行多变量分析得出的预测死亡的独立因素包括乳酸脱氢酶水平、治疗前 Epstein-Barr 病毒 DNA、局部病灶的总病变糖酵解、转移病灶数量和年龄，所有这些因素被组合成一个包含（提名图 B）或不包含 PET-CT 参数（提名图 A）的提名图。提名图 B 预测死亡的 C 指数为 0.70，明显高于提名图 A 的 C 指数值。低风险组的中位 OS 明显高于高风险组（69.60 个月 [95 % CI: 58.50-108.66] vs. 21.40 个月 [95 % CI: 19.20-23.90]; p＜0.01）。所有结果均在验证队列中得到证实：包括 PET-CT 参数在内的提名图能准确预测 dmNPC 患者的预后，从而对这些患者进行有效的风险分层。

{"title":"The prognostic value of pretreatment 18F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma","authors":"Li-wen Gu , Xu Zhang , Jing Zhang , Bei-bei Xiao , Li-ping Wu , Lin-quan Tang , Ling Guo , Li-ting Liu","doi":"10.1016/j.oraloncology.2024.106928","DOIUrl":"10.1016/j.oraloncology.2024.106928","url":null,"abstract":"<div><h3>Background and purpose</h3><p>To develop and validate a prognostic nomogram based on pretreatment <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT)radiomics parameters and peripheral blood markers for risk stratification in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC).</p></div><div><h3>Materials and Methods</h3><p>A total of 558 patients with dmNPC were retrospectively enrolled between 2011 and 2019. Eligible patients were randomly divided into training and validation cohorts (7:3 ratio). A Cox regression model was used to identify prognostic factors for overall survival (OS). The predictive accuracy and discriminative ability of the prognostic nomogram were determined using the concordance index (C-index) and calibration curve.</p></div><div><h3>Results</h3><p>Independent factors derived from multivariable analysis of the training cohort to predict death were lactate dehydrogenase levels, pretreatment Epstein–Barr virus DNA, total lesion glycolysis of locoregional lesions, number of metastatic lesions, and age, all of which were assembled into a nomogram with (nomogram B) or without PET-CT parameters (nomogram A). The C-index of nomogram B for predicting death was 0.70, which was significantly higher than the C-index values for nomogram A. Patients were then stratified into low- and high-risk groups based on the scores calculated using nomogram B for OS. The median OS was significantly higher in the low-risk group than in the high-risk group (69.60 months [95 % CI: 58.50–108.66] vs. 21.40 months [95 % CI: 19.20–23.90]; p＜0.01). All the results were confirmed in the validation cohort.</p></div><div><h3>Conclusion</h3><p>The proposed nomogram including PET-CT parameters yielded accurate prognostic predictions for patients with dmNPC, enabling effective risk stratification for these patients.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on “Utilizing deep learning for automated detection of oral lesions: A multicenter study” 关于 "利用深度学习自动检测口腔病变：一项多中心研究 "发表评论。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106932

Sesuraj Balasamy, Ashok K. Sundramoorthy

引用次数: 0

Comment on the “Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module” 就 "使用 FACE-Q 头颈癌模块评估 583 名头颈癌幸存者的生活质量 "发表评论。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106934

Hemashree Kasirajan , Gayathri Rengasamy , Vishnu Priya Veeraraghavan

引用次数: 0

Correspondence on “Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040” 关于 "儿童和青少年鼻咽癌的全球负担：至 2040 年的趋势和预测"。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106933

Deepavalli Arumuganainar , Saravanan Sekaran

引用次数: 0

Letter to the editor, “Letter to the editor, “Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.” 致编辑的信，"致编辑的信，"局部晚期鼻咽癌的短期与长期节律辅助化疗：倾向评分匹配真实世界研究"。

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2024-07-04 DOI: 10.1016/j.oraloncology.2024.106935

Geetha Shanmugam

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Oral oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀